Table 1

Demographic details of the two different patient cohorts used for genotyping and gene expression studies.

225 patients for ADORA polymorphisms

20 patients for synovial gene expression

Age (years)

59.5 (18 to 84)

66.4 (48 to 80)

% Female

72%

90%

Disease duration (years)

10.4 (0.17 to 57)

21.1 (3.7 to 47)

Nodules

56 (24.9%)

12 (60%)

Erosions

139 (61.8%)

19 (95%)

RF +positive

178 (79.1%)

17 (85%)

CCP positive

165/214 (77.1%)

11/15 (73.3%)

Receiving MTX

225 (100%)

11 (55%)

MTX dose (mean) (mg/wk)

15.8 (5 to 25)

16.4 (7.5 to 20)

ESR

16.6 (2 to 96)

41.4 (14 to 74) (n = 10)

CRP

10.9 (0 to 150)

18.9 (3 to 79) (n = 17)

Anti-TNF therapy

0

3 (15%)

Prednisone

71 (31.6%)

6 (30%)

ADOR, adenosine receptor; CCP, cyclic citrullinated peptide; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MTX, methotrexate; TNF, tumor necrosis factor; RF, rheumatoid factor.

Stamp et al. Arthritis Research & Therapy 2012 14:R138   doi:10.1186/ar3871